84791Neucruit: Creating a platform to optimise participant recruitment for active COVID-19 vaccine trials, and future clinical and research trials.ClosedCollaborative R&DInnovate UKClinical research trials protect patients from experimental medical research and ensure that new vaccinations are safe and effective before they're scaled. On average, researchers spend 30% of R&D securing participant recruitment. When the criteria for participation is complex, it can take up to 7 months to find participants (CRM International-2011). Over 86% of clinical research is delayed by up to 6-months due to delays in participant recruitment, translating into even longer delays for patients who need life-saving treatments (Applied Clinical Trials-2004). To understand the nature, effects and suppression of COVID-19, extensive trials are needed. Trials are likely to include vaccinations and asymptomatic patient testing to understand how the disease is spread. There are approximately 150 COVID-19 vaccination trials awaiting testing, requiring on average 650 participants per trial (Harden-2018). Research facilities around the world are attempting to urgently fast-track a vaccine. Access to a network of pre-screened participants will make vaccinations a reality, quickly. Neucruit's innovation combines an optimised platform for managing recruitment of clinical trials, with intelligent algorithms for pre-selection and matching using AI. Neucruit will optimise participant recruitment via a web-based platform, which matchmakes clinical researchers with a large population of patients, and digitalises contact time for risk reduction. In this project we will develop the Neucruit platform to MVP, onboard a minimum 9,000 participants and test our software in three live Phase III COVID-19 vaccination trials.